Hubei Cancer Hospital ( Site 3125)

Wuhan, Hubei 430079

1 studies enrolling now · 1 studies all time

What they study most

Diffuse Large B-Cell Lymphoma

Studies at this site

• A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) — Recruiting now